a Netherlands Pharmacovigilance Centre Lareb , 's-Hertogenbosch , The Netherlands.
b Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, - Epidemiology & -Economics, University of Groningen , Groningen , The Netherlands.
Expert Opin Drug Saf. 2019 Sep;18(9):869-874. doi: 10.1080/14740338.2019.1645120. Epub 2019 Jul 22.
: Non-vitamin K oral anticoagulants (NOACs) are a relatively new group of anticoagulants. Characteristics of adverse drug reactions (ADRs) as experienced by patients in everyday use have not yet been fully clarified. The aim was to gain insight into the safety profile of NOACs from a patient's perspective. : This was a prospective, observational web-based cohort event monitoring study among first-time users of NOACs. Patients were recruited between July 2012 and April 2017. They were invited to complete four web-based questionnaires 2 weeks, 5 weeks, 3 months and 6 months after starting treatment. Information was collected about patient characteristics, drug use, and characteristics of ADRs. : 1748 NOAC users were included. 661 (38%) experienced at least one ADR. The reported ADRs were comparable with the information described in the Summary of Product Characteristics and generally occurred within 1 week after the start. In 59% of ADRs the patients recovered. These ADRs had no impact on the use and dosage of the NOAC in 68%. In total, 9% of the patients discontinued the NOAC because of ADRs. : Overall NOACs were well tolerated by the participants. Most reported ADRs occurred within 1 week after the start. Patients recovered from most ADRs without changes to the use of the NOAC.
: 非维生素 K 口服抗凝剂(NOACs)是一组相对较新的抗凝剂。患者在日常使用中经历的不良反应(ADRs)特征尚未完全阐明。目的是从患者的角度了解 NOACs 的安全性概况。 : 这是一项针对首次使用 NOACs 的患者的前瞻性、观察性、基于网络的队列事件监测研究。患者于 2012 年 7 月至 2017 年 4 月期间招募。他们被邀请在开始治疗后 2 周、5 周、3 个月和 6 个月时完成四次基于网络的问卷。收集了有关患者特征、药物使用以及 ADR 特征的信息。 : 共纳入 1748 名 NOAC 用户。661 名(38%)至少经历了一次 ADR。报告的 ADR 与产品特性摘要中描述的信息相似,通常发生在开始后 1 周内。59%的 ADR 患者康复。这些 ADR 对 68%的 NOAC 的使用和剂量没有影响。共有 9%的患者因 ADR 而停止使用 NOAC。 : 总体而言,NOACs 被参与者耐受良好。大多数报告的 ADR 发生在开始后 1 周内。大多数 ADR 患者无需更改 NOAC 的使用即可康复。